<p>Fennec Pharmaceuticals Inc.（TSE:FRX - 获取免费报告）高级官员罗伯特·克里斯托弗·安德拉德于 6 月 2 日星期一购买了 8,220 股该公司的股票。每股的平均购买成本为 6.99 加元，总交易额为 57,433.14 加元。</p>
<p>获取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
<h2>Fennec Pharmaceuticals 股价上涨 1.5%</h2>
<p>FRX 股票在周三的午盘交易中上涨了 0.17 加元，达到 11.33 加元。该股票成交 136 股，成交量低于其平均成交量 1,205 股。该股票的 50 日移动平均线为 8.64 加元，200 日移动平均线为 8.81 加元。该公司的市值为 2.185 亿加元，市盈率为-191.93，贝塔值为 0.25。Fennec Pharmaceuticals Inc. 的 52 周低点为 5.65 加元，52 周高点为 11.68 加元。该公司的流动比率为 7.80，速动比率为 10.17，负债权益比为-620.83。</p>
<h2>关于 Fennec Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Fennec Pharmaceuticals Inc. 是一家在美国运营的生物制药公司。该公司的产品候选包括 PEDMARK，一种用于预防铂类药物引起的儿童癌症患者耳毒性的硫代硫酸钠制剂。它通过区域儿童肿瘤学专家和医学科学联络员销售其产品。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Fennec Pharmaceuticals</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>Guidewire 大幅上涨：超过 300 美元的可能性</li>
<li>如何捕捉股息增加的好处</li>
<li>模拟器件的周期性复苏故事刚刚开始</li>
<li>3 只股票引领迷因股复兴</li>
<li>Joby 与沙特的谅解备忘录：强劲的初步反应遇到市场动态</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9RlJY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9RlJY"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Fennec Pharmaceuticals 吗？</h2>
<p>在考虑 Fennec Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Fennec Pharmaceuticals 并不在名单上。</p>
<p>虽然 Fennec Pharmaceuticals 目前在分析师中获得了强烈买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

FENC

<p>罗伯特·克里斯托弗·安德拉德（Robert Christopher Andrade），Fennec Pharmaceuticals Inc.（TSE:FRX）的高级官员，于 6 月 2 日以每股平均 6.99 加元的价格购买了 8,220 股公司股票，总计 57,433.14 加元。在此交易之后，Fennec 的股票上涨了 1.5%，达到了 11.33 加元。该公司的市值为 2.185 亿加元，市盈率为-191.93。Fennec Pharmaceuticals 专注于生物制药，特别是在儿童肿瘤学领域</p>

<p>Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Senior Officer Robert Christopher Andrade bought 8,220 shares of the company's stock in a transaction on Monday, June 2nd. The stock was bought at an average cost of C$6.99 per share, for a total transaction of C$57,433.14.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc.（TSE:FRX - 获取免费报告）高级官员罗伯特·克里斯托弗·安德拉德于 6 月 2 日星期一购买了 8,220 股该公司的股票。每股的平均购买成本为 6.99 加元，总交易额为 57,433.14 加元。</p>
</div><p>Get <strong>Fennec Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Fennec Pharmaceuticals Trading Up 1.5%</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 股价上涨 1.5%</h2>
</div><p>FRX stock traded up C$0.17 during mid-day trading on Wednesday, reaching C$11.33. 136 shares of the stock traded hands, compared to its average volume of 1,205. The stock's fifty day moving average is C$8.64 and its 200-day moving average is C$8.81. The company has a market cap of C$218.50 million, a P/E ratio of -191.93 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a 52-week low of C$5.65 and a 52-week high of C$11.68. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.</p>
<div class="lb-trans"><p>FRX 股票在周三的午盘交易中上涨了 0.17 加元，达到 11.33 加元。该股票成交 136 股，成交量低于其平均成交量 1,205 股。该股票的 50 日移动平均线为 8.64 加元，200 日移动平均线为 8.81 加元。该公司的市值为 2.185 亿加元，市盈率为-191.93，贝塔值为 0.25。Fennec Pharmaceuticals Inc. 的 52 周低点为 5.65 加元，52 周高点为 11.68 加元。该公司的流动比率为 7.80，速动比率为 10.17，负债权益比为-620.83。</p>
</div><h2>About Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Fennec Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc. 是一家在美国运营的生物制药公司。该公司的产品候选包括 PEDMARK，一种用于预防铂类药物引起的儿童癌症患者耳毒性的硫代硫酸钠制剂。它通过区域儿童肿瘤学专家和医学科学联络员销售其产品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Fennec Pharmaceuticals</li>
<li>Golden Cross Stocks: Pattern, Examples and Charts</li>
<li>Guidewire Rockets Higher: A Move Above $300 Is Probable</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Analog Devices' Cyclical Recovery Story Has Just Begun</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Joby's Saudi MoU: Strong Initial Reaction Meets Market Dynamics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Fennec Pharmaceuticals</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>Guidewire 大幅上涨：超过 300 美元的可能性</li>
<li>如何捕捉股息增加的好处</li>
<li>模拟器件的周期性复苏故事刚刚开始</li>
<li>3 只股票引领迷因股复兴</li>
<li>Joby 与沙特的谅解备忘录：强劲的初步反应遇到市场动态</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9RlJY" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=TSE&amp;Symbol=FRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Fennec Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Fennec Pharmaceuticals 吗？</h2>
</div><p>Before you consider Fennec Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Fennec Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Fennec Pharmaceuticals 并不在名单上。</p>
</div><p>While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Fennec Pharmaceuticals 目前在分析师中获得了强烈买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

罗伯特·克里斯托弗·安德拉德购入了 8,220 股 Fennec Pharma（TSE:FRX）的股票